Eisai hit with Cancer Drugs Fund 'double Whammy'

Eisai has managed to ensure patients in England get access to its end-of-life breast cancer drug Halaven (eribulin), but at a big cost to the company that will have a "direct impact on its activity in the UK". The firm also complained it had been hit with a "double whammy" from the Cancer Drugs Fund after it said it wouldn't be assessing Lenvima (lenvatinib) for thyroid cancer.

Eisai has managed to ensure patients in England get access to its end-of-life breast cancer drug Halaven (eribulin), but at a big cost to the company that will have a "direct impact on its activity in the UK". The firm also complained it had been hit with a "double whammy" from the Cancer Drugs Fund after it said it wouldn't be assessing Lenvima (lenvatinib) for thyroid cancer.

Nick Burgin, president of Eisai's global value & access unit, declined to give further detail on the agreement it had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Prasad’s Exit From CBER Could Bode Well For Genetic Medicines

 

Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

More from Therapy Areas

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.

Prasad’s Exit From CBER Could Bode Well For Genetic Medicines

 

Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.